<DOC>
	<DOCNO>NCT01126749</DOCNO>
	<brief_summary>The purpose study determine whether Patients Locally Advanced Metastatic Bladder Cancer receive Eribulin Mesylate Administered Combination Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone First-Line Therapy safety tolerable administered patient locally advance metastatic bladder cancer gain preliminary data whether patient may benefit combination . experience benefit .</brief_summary>
	<brief_title>Eribulin Mesylate Administered Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone First-Line Therapy Locally Advanced Metastatic Bladder Cancer</brief_title>
	<detailed_description>This open-label , multicenter , randomize study consist 2 phase : - Phase Ib : safety run-in period 3 ascending dos eribulin ; - Phase II : randomize 2-arm design . Phase Ib Patients recruit cohort , minimum 3 maximum 6 patient per cohort . All patient receive dose gemcitabine ( 1000 mg/m2 Days 1 8 21-day cycle ) cisplatin ( 70 mg/m2 Day 1 ) combination eribulin ( administered Days 1 8 cycle ) . All patient cohort receive dose level eribulin . The dose level eribulin escalate additional cohort unless great 2 dose limit toxicity ( DLTs ) report low dose level ( ) prior enrollment next dose level . If one DLT occur dose level , cohort expand include maximum 6 patient . A Dose Escalation Committee determine dose escalation appropriate whether MTD define precede dose intermediate dose . Phase II Patients randomize 1:1 ratio receive either eribulin combination gemcitabine plus cisplatin ( Arm 1 ) gemcitabine plus cisplatin alone ( Arm 2 ) . The eribulin dose 1.0 mg/m2 administer Days 1 8 21-day treatment cycle , recommend Phase II dose eribulin administer combination gemcitabine plus cisplatin , determine Phase Ib portion study . Allocation patient stratify base metastatic disease status ( patient visceral metastasis versus patient non-visceral metastasis ) . This stratified randomization centrally allocate across center via Interactive Voice Activated Response System ( IVRS ) . For Phase Ib Phase II portion , 1 cycle therapy last 21 day , maximum number 6 gemcitabine plus cisplatin cycle . Radiologic examination include compute tomography ( CT ) scan chest , abdomen , pelvis appropriate ( CT magnetic resonance image [ MRI ] scan appropriate ) , perform Screening every 6 week therapy . In case dose delay , scan perform accord original Cycle 1 Day 1 schedule ( ie , scan delay ) . Radiographic assessment repeat withdrawal last assessment obtain &gt; 3 week withdrawal therapy . Patients follow death follow completion therapy . Scans require every 2 month documentation PD start next line therapy , whichever occur first . In patient experience PD , follow-up survival radiographic scan require</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Criteria Patients may enter study meet follow criterion : 1 . Male female patient &gt; 18 year age ; 2 . Histologically cytologically confirm , locally advanced Stage 4 ( eg , T4b ) metastatic transitional cell cancer bladder ; include transitional cell cancer urothelium ( prostate , urethra , ureter , renal pelvis ) 3 . Not previously treat systemic chemotherapy metastatic bladder cancer ( one regimen adjuvant neoadjuvant chemotherapy permit ) . Patients must diseasefree interval 6 month adjuvant therapy ; 4 . At least 1 site measurable disease Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST version 1.1 ) guideline ; 5 . Life expectancy great equal 3 month ; 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 ; 7 . Patients must active bowel function define least 3 bowel movement per week accord subject history must willing maintain diary bowel function prior dose continue completion study treatment . Laxatives may use maintain adequate bowel function ; 8 . Patients must adequate renal function evidence calculated creatinine clearance great equal 55 mL/min per Cockcroft Gault formula ; 9 . Patients must adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 X 109/L , hemoglobin great equal 10.0 g/dL ( hemoglobin le 10.0 g/dL Screening acceptable correct great equal 10.0 g/dL growth factor transfusion prior first dose ) , platelet count great equal 100 X 109/L ; 10 . Patients must adequate liver function evidence bilirubin less equal 1.5 time upper limit normal range ( ULN ) , alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 X ULN ( case liver metastasis , less equal 5 X ULN ) . If bone metastasis , liverspecific alkaline phosphatase may separate total use ass liver function instead total alkaline phosphatase ; 11 . Male female patient childproducing potential must agree use double barrier contraception , oral contraceptive , avoidance pregnancy measure study 90 day last day treatment ; 12 . Females childbearing potential must negative serum pregnancy test screening ; 13 . Females may breastfeed ; 14 . Ability understand willingness sign write informed consent . Exclusion Criteria Patients enter study follow reason : 1 . Prior treatment epothilone , ixabepilone , patupilone , vinflunine , halichondrin B , and/or halichondrin B chemical derivative ; 2 . History malignancy except : ( 1 ) adequately treat basal squamous cell carcinoma skin ; ( 2 ) curatively treat , ) situ carcinoma uterine cervix , b ) prostate cancer , c ) superficial bladder cancer ; ( 3 ) curatively treat solid tumor evidence disease great equal 3 year ; 3 . Presence brain metastasis , unless patient received adequate treatment least 4 week prior randomization , stable , asymptomatic , steroid least 4 week prior randomization ; 4 . Received investigational agent , chemotherapy , biological therapy , hormonal therapy , target therapy , radiotherapy within 30 day prior commence study treatment , recover treatmentrelated toxicity Common Toxicity Criteria ( CTC ) Grade le equal 1 , except alopecia ; 5 . Are currently receive investigational agent systemic anticancer treatment , include palliative radiotherapy ; 6 . Significant cardiovascular impairment ( history congestive heart failure New York Heart Association [ NYHA ] Grade &gt; 2 , unstable angina myocardial infarction within past 6 month , serious cardiac arrhythmia ) ; 7 . Subjects high probability Long QT Syndrome ; 8 . Patients organ allograft require immunosuppression ; 9 . Known active infection human immunodeficiency virus ( HIV ) , hepatitis B , virus ( HBV ) hepatitis C ; virus ( HCV ) ; 10 . Hypersensitivity halichondrin B and/or halichondrin B chemical derivative 11 . Prior pelvic radiation ; 12 . History know suspect peritoneal carcinomatosis risk bleed perforation , intraluminal serosal metastatic lesion risk bleed perforation lesion ; 13 . History abdominal adhesion , fistula , diverticulitis , gastrointestinal perforation , intraabdominal abscess , document peptic ulcer disease ( active gastroesophageal reflux disease/dyspepsia allow ) , gastrointestinal condition increase risk perforation ; 14 . Common Terminology Criteria Adverse Events , version 4.0 ( CTCAE v.4.0 ) Grade great equal 2 constipation ; 15 . CTCAE v.4.0 Grade great equal 2 peripheral neuropathy ; 16 . Have medical condition would interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Locally Advanced Metastatic Bladder Cancer , include transitional cell cancer urothelium ( prostate , urethra , ureter , renal pelvis )</keyword>
</DOC>